Exocrine Pancreatic Insufficiency - Pipeline Review, H2

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Exocrine Pancreatic Insufficiency Pipeline Review, H2 2017, provides an overview of the Exocrine Pancreatic Insufficiency Gastrointestinal pipeline landscape.

Exocrine pancreatic insufficiency EPI is a condition characterized by deficiency of the exocrine pancreatic enzymes, resulting in the inability to digest food properly, or maldigestion. Symptoms include diarrhea, loose, oily stools with unabsorbed fat steatorrhea, vitamin deficiencies, loss of appetite, and unexplained weight loss. Treatment includes pancreatic enzyme replacement therapy PERT and lifestyle modifications.

Download FREE Sample of this Report @ https://www.24marketreports.com/report-sample/exocrine-pancreatic-insufficiency---pipeline-review-h2-2017-market-34

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Exocrine Pancreatic Insufficiency Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Exocrine Pancreatic Insufficiency Gastrointestinal, complete with analysis by stage of development, drug target, mechanism of action MoA, route of administration RoA and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Exocrine Pancreatic Insufficiency Gastrointestinal pipeline guide also reviews of key players involved in therapeutic development for Exocrine Pancreatic Insufficiency and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 1 respectively.

Exocrine Pancreatic Insufficiency Gastrointestinal pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Exocrine Pancreatic Insufficiency Gastrointestinal.
The pipeline guide reviews pipeline therapeutics for Exocrine Pancreatic Insufficiency Gastrointestinal by companies and universities/research institutes based on information derived from company and industryspecific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from preregistration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Exocrine Pancreatic Insufficiency Gastrointestinal therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Exocrine Pancreatic Insufficiency Gastrointestinal therapeutics based on mechanism of action MoA, drug target, route of administration RoA and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Exocrine Pancreatic Insufficiency Gastrointestinal
Get the Complete Report & TOC @ https://www.24marketreports.com/life-sciences/exocrine-pancreatic-insufficiency---pipeline-review-h2-2017-market-34

Table of content

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Exocrine Pancreatic Insufficiency Overview
Exocrine Pancreatic Insufficiency Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Exocrine Pancreatic Insufficiency Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Exocrine Pancreatic Insufficiency Companies Involved in Therapeutics Development
Anthera Pharmaceuticals Inc
Celleron Therapeutics Ltd
Cilian AG
Laboratoires Mayoly Spindler SAS
Nordmark Arzneimittel GmbH & Co KG
Exocrine Pancreatic Insufficiency Drug Profiles
burlulipase Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cilase Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CXD101 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
liprotamase Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MS1819 Drug Profile
Product Description
Mechanism Of Action

If You Have Any Question Related To This Report Contact Us @ https://www.24marketreports.com/enquire-now/exocrine-pancreatic-insufficiency---pipeline-review-h2-2017-market-34

CONTACT US:
276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170
Fax: (+1) 212 634 4885
Email: [email protected]

Follow Us On linkedin :- https://www.linkedin.com/company/24-market-reports